

Carol R Bradford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3721117/publications.pdf>

Version: 2024-02-01

117
papers

5,184
citations

87723

38
h-index

95083

68
g-index

117
all docs

117
docs citations

117
times ranked

6427
citing authors

#	ARTICLE	IF	CITATIONS
1	Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results. <i>Journal of Clinical Oncology</i> , 2010, 28, 2732-2738.	0.8	305
2	Tobacco Use in Human Papillomavirus-Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence. <i>Clinical Cancer Research</i> , 2010, 16, 1226-1235.	3.2	271
3	Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 1074-1084.	0.9	259
4	Single-Cycle Induction Chemotherapy Selects Patients With Advanced Laryngeal Cancer for Combined Chemoradiation: A New Treatment Paradigm. <i>Journal of Clinical Oncology</i> , 2006, 24, 593-598.	0.8	240
5	COVID-19 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. <i>Head and Neck</i> , 2020, 42, 1259-1267.	0.9	218
6	Pain, Quality of Life, and Spinal Accessory Nerve Status After Neck Dissection. <i>Laryngoscope</i> , 2000, 110, 620-626.	1.1	192
7	Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. <i>Head and Neck</i> , 2016, 38, E2151-8.	0.9	146
8	P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. <i>Head and Neck</i> , 2003, 25, 654-661.	0.9	144
9	Update on primary head and neck mucosal melanoma. <i>Head and Neck</i> , 2016, 38, 147-155.	0.9	143
10	Development and Validation of the Neck Dissection Impairment Index. <i>JAMA Otolaryngology</i> , 2002, 128, 44.	1.5	135
11	Functional assessment using Constant's Shoulder Scale after modified radical and selective neck dissection. <i>Head and Neck</i> , 2002, 24, 432-436.	0.9	129
12	Reversal of cisplatin resistance with a BH3 mimetic, (âˆ™)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1096-1104.	1.9	116
13	Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate. <i>Head and Neck</i> , 2015, 37, 134-150.	0.9	106
14	High-Risk Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and Oral Cavity Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 1320.	1.2	93
15	Health Impact of Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 1999, 120, 852-859.	1.1	82
16	The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2018, 10, 267.	1.7	81
17	Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. <i>Cancer</i> , 2012, 118, 1040-1047.	2.0	79
18	Chemoprophylaxis for Venous Thromboembolism in Otolaryngology. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 999.	1.2	70

#	ARTICLE	IF	CITATIONS
19	Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 234-239.	0.8	68
20	Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. <i>Oral Oncology</i> , 2017, 68, 5-8.	0.8	67
21	Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 1999, 121, 534-538.	1.1	65
22	Squamous Carcinoma of the Head and Neck in Organ Transplant Recipients. <i>Laryngoscope</i> , 1990, 100, 190-194.	1.1	63
23	Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. <i>Oral Oncology</i> , 2012, 48, 918-922.	0.8	62
24	Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 513-519.	0.8	62
25	Free Tissue Reconstruction of the Hypopharynx After Organ Preservation Therapy: Analysis of Wound Complications. <i>Laryngoscope</i> , 2001, 111, 1192-1196.	1.1	61
26	Contemporary management of primary parapharyngeal space tumors. <i>Head and Neck</i> , 2019, 41, 522-535.	0.9	61
27	Parathyroid cancer: An update. <i>Cancer Treatment Reviews</i> , 2020, 86, 102012.	3.4	58
28	Second Place " Resident Clinical Science Award 1995: Human Papillomavirus Types Important in Progression of Inverted Papilloma. <i>Otolaryngology - Head and Neck Surgery</i> , 1995, 113, 558-563.	1.1	57
29	Management of the facial nerve in parotid cancer: preservation or resection and reconstruction. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 2615-2626.	0.8	57
30	Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 77, 83-89.	0.8	53
31	Head and Neck Cancer: A Review of the Impact of Treatment Delay on Outcome. <i>Advances in Therapy</i> , 2018, 35, 153-160.	1.3	52
32	Skin cancer of the head and neck with gross or microscopic perineural involvement: Patterns of failure. <i>Radiotherapy and Oncology</i> , 2016, 120, 81-86.	0.3	50
33	Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. <i>Oral Oncology</i> , 2020, 101, 104521.	0.8	48
34	The risk of second primary tumors in head and neck cancer: A systematic review. <i>Head and Neck</i> , 2020, 42, 456-466.	0.9	47
35	Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in Advanced Laryngeal Cancer. <i>JAMA Otolaryngology</i> , 2008, 134, 363.	1.5	46
36	Occult Nodal Disease Prevalence and Distribution in Recurrent Laryngeal Cancer Requiring Salvage Laryngectomy. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 154, 473-479.	1.1	45

#	ARTICLE	IF	CITATIONS
37	Prognostic factors in laryngeal squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 74-81.	0.6	44
38	Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma. <i>Molecular Cancer Research</i> , 2016, 14, 941-952.	1.5	43
39	Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine. <i>Genes and Cancer</i> , 2016, 7, 182-200.	0.6	41
40	Biomarkers in advanced larynx cancer. <i>Laryngoscope</i> , 2014, 124, 179-187.	1.1	40
41	Prioritizing Diversity in Otolaryngologyâ€œHead and Neck Surgery: Starting a Conversation. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 229-233.	1.1	40
42	Analysis of recurrence, complications, and functional results with free jejunal flaps. <i>Head and Neck</i> , 1994, 16, 149-154.	0.9	38
43	Identification of Targetable <i>ERBB2</i> Aberrations in Head and Neck Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 559.	1.2	37
44	Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 213-220.	2.0	36
45	Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 184-190.	0.9	35
46	Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 2512-2518.	0.9	35
47	Head and neck squamous cell carcinoma of unknown primary: Neck dissection and radiotherapy or definitive radiotherapy. <i>Head and Neck</i> , 2014, 36, 1589-1595.	0.9	34
48	Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. <i>Head and Neck</i> , 2017, 39, 840-852.	0.9	34
49	Pathogenetic Analysis of Sinonasal Teratocarcinomas Reveal Actionable β -catenin Overexpression and a β -catenin Mutation. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, 346-352.	0.4	34
50	Efficacy of Induction Selection Chemotherapy vs Primary Surgery for Patients With Advanced Oral Cavity Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 134.	1.2	33
51	Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials. <i>Auris Nasus Larynx</i> , 2017, 44, 18-25.	0.5	32
52	Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 355.	1.2	32
53	Epigenetic alterations in metastatic cutaneous carcinoma. <i>Head and Neck</i> , 2015, 37, 994-1001.	0.9	31
54	Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. <i>Head and Neck</i> , 2016, 38, E1646-52.	0.9	31

#	ARTICLE	IF	CITATIONS
55	Predictors of severe long-term toxicity after re-irradiation for head and neck cancer. <i>Oral Oncology</i> , 2016, 60, 32-40.	0.8	30
56	In vivo Wnt pathway inhibition of human squamous cell carcinoma growth and metastasis in the chick chorioallantoic model. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2016, 45, 26.	0.9	30
57	A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. <i>Investigational New Drugs</i> , 2016, 34, 481-489.	1.2	30
58	11p Deletions and breakpoints in squamous cell carcinoma: Association with altered reactivity with the UM-E7 antibody. <i>Genes Chromosomes and Cancer</i> , 1991, 3, 272-282.	1.5	29
59	Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 857-864.	0.9	28
60	Targeting Apoptosis to Overcome Cisplatin Resistance: A Translational Study in Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S106-S108.	0.4	27
61	Hypothyroidism and Wound Healing After Salvage Laryngectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1288-1295.	0.7	26
62	The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review. <i>Head and Neck</i> , 2019, 41, 2410-2429.	0.9	24
63	IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence. <i>Neoplasia</i> , 2016, 18, 273-281.	2.3	23
64	Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. <i>Head and Neck</i> , 2014, 36, 617-623.	0.9	22
65	Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2877-2894.	0.8	22
66	Classification of TP53 mutations and HPV predict survival in advanced larynx cancer. <i>Laryngoscope</i> , 2016, 126, E292-E299.	1.1	20
67	NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas. <i>BMC Cancer</i> , 2015, 15, 825.	1.1	18
68	Preoperative Tracheostomy Is Associated with Poor Disease-Free Survival in Recurrent Laryngeal Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 432-438.	1.1	18
69	The natural history of thin melanoma and the utility of sentinel lymph node biopsy. <i>Journal of Surgical Oncology</i> , 2017, 116, 1185-1192.	0.8	18
70	Positron emission tomography-CT prediction of occult nodal metastasis in recurrent laryngeal cancer. <i>Head and Neck</i> , 2017, 39, 980-987.	0.9	17
71	Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. <i>Head and Neck</i> , 2016, 38, E459-67.	0.9	16
72	Understanding Interactions of Smoking on Prognosis of HPV-Associated Oropharyngeal Cancers. <i>Advances in Therapy</i> , 2018, 35, 255-260.	1.3	16

#	ARTICLE	IF	CITATIONS
73	Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation. <i>Oral Oncology</i> , 2016, 54, 68-74.	0.8	15
74	Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation. <i>Oral Oncology</i> , 2021, 121, 105332.	0.8	15
75	Planned Early Neck Dissection Before Radiation for Persistent Neck Nodes After Induction Chemotherapy. <i>Laryngoscope</i> , 1997, 107, 1129-1137.	1.1	14
76	Total versus superficial parotidectomy for stage III melanoma. <i>Head and Neck</i> , 2017, 39, 1665-1670.	0.9	14
77	“My Research Is Their Business, but I’m Not Their Business” Patient and Clinician Perspectives on Commercialization of Precision Oncology Data. <i>Oncologist</i> , 2020, 25, 620-626.	1.9	13
78	Speech and swallowing outcomes after laryngectomy for the dysfunctional irradiated larynx. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 1459-1465.	0.8	13
79	Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells. <i>Laryngoscope</i> , 2016, 126, E184-90.	1.1	12
80	Removing the Taboo on the Surgical Violation (Cut-Through) of Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 1010.	1.2	11
81	Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 313.	1.2	11
82	Mutational profiles of persistent/recurrent laryngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 423-428.	0.9	11
83	Patient and Provider Perspectives Regarding Enrollment in Head and Neck Cancer Research. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 162, 73-78.	1.1	10
84	Selective Neck Dissection Is an Option for Early Node-Positive Disease. <i>JAMA Otolaryngology</i> , 2004, 130, 1436.	1.5	8
85	UM-SCC-103. <i>Annals of Otology, Rhinology and Laryngology</i> , 2014, 123, 662-672.	0.6	8
86	The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2014, 35, 226-232.	0.6	8
87	Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 155, 106-112.	1.1	8
88	Elective Paratracheal Lymph Node Dissection in Salvage Laryngectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2542-2548.	0.7	8
89	Patient Burden with Current Surveillance Paradigm and Factors Associated with Interest in Altered Surveillance for Early Stage HPV-Related Oropharyngeal Cancer. <i>Oncologist</i> , 2021, 26, 676-684.	1.9	8
90	Honesty and Transparency, Indispensable to the Clinical Mission—Part II. <i>Otolaryngologic Clinics of North America</i> , 2022, 55, 63-82.	0.5	8

#	ARTICLE	IF	CITATIONS
91	Expression of Human Papillomavirus 6 in Inverted Papilloma Arising in a Renal Transplant Recipient. <i>Laryngoscope</i> , 1998, 108, 115-119.	1.1	7
92	Neck spasm after chemoradiotherapy for head and neck cancer: Natural history and dosimetric correlates. <i>Head and Neck</i> , 2014, 36, 176-180.	0.9	7
93	Phase I Trial of Radiotherapy Concurrent with Twice-Weekly Gemcitabine for Head and Neck Cancer: Translation From Preclinical Investigations Aiming to Improve the Therapeutic Ratio. <i>Translational Oncology</i> , 2014, 7, 479-483.	1.7	7
94	Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 995-997.	1.1	7
95	Upholding the Tripartite Mission in Times of Crisis: Purpose and Perseverance in the COVID-19 Pandemic. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 54-59.	1.1	7
96	The Care of the Head and Neck Cancer Patient Is a Team Sport. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 337.	1.2	6
97	When is chemotherapy in head and neck squamous cell carcinoma not indicated?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 781-787.	0.8	6
98	Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. <i>Head and Neck</i> , 2020, 42, 1728-1737.	0.9	6
99	Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 625-630.	1.1	5
100	T4 Laryngeal Cancer With Good Function: Should We Be Reluctant to Treat Without Surgery?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1400-1403.	0.4	5
101	Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2022, 44, 1192-1205.	0.9	5
102	Cranial nerve outcomes in regionally recurrent head & neck melanoma after sentinel lymph node biopsy. <i>Laryngoscope</i> , 2020, 130, 1707-1714.	1.1	4
103	Implementation of an Intramural Competitive Resident Research Grant. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 156, 1114-1118.	1.1	3
104	Work-Life Balance Among Head and Neck Surgeons—Seeking Visionary Leadership From Everywhere. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 458.	1.2	3
105	Predictors of survival in patients undergoing oropharyngeal surgery for cancer recurrence after radiation therapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2085-2093.	0.8	3
106	Functional outcomes and tracheostomy dependence following salvage oropharyngeal surgery. <i>Oral Oncology</i> , 2021, 113, 105034.	0.8	3
107	Incidence and Prognosis of Cutaneous Melanoma Involving the Head and Neck. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2628.	3.8	2
108	Long-term neck and shoulder function among survivors of oropharyngeal squamous cell carcinoma treated with chemoradiation as assessed with the neck dissection impairment index. <i>Head and Neck</i> , 2021, 43, 1621-1628.	0.9	2

#	ARTICLE	IF	CITATIONS
109	Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-2 inhibitor. <i>Head and Neck</i> , 2022, , .	0.9	2
110	Neurologic late effects associated with radiologic evidence of vertebral osteoradionecrosis after salvage laryngectomy: A syndrome associated with survivors of laryngeal and hypopharyngeal cancer. <i>Head and Neck</i> , 2016, 38, 1187-1193.	0.9	1
111	Decision Making for Diagnosis and Management. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 783-792.	0.5	1
112	Impact of extrinsic tongue muscle invasion on stage migration in AJCC 8th edition staging of oral cavity carcinoma. <i>Oral Oncology</i> , 2020, 110, 104888.	0.8	1
113	Operational Constraints and Gender Biases: A Qualitative Analysis of Physician Parenting Experiences. <i>Women S Health Reports</i> , 2022, 3, 297-306.	0.4	1
114	Incidental Masticator Space Lesion in a Teenager. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 577.	1.2	0
115	In reply: Management of thin melanoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 536-536.	0.8	0
116	Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines. <i>Nagoya Journal of Medical Science</i> , 2020, 82, 519-531.	0.6	0
117	Imaging response assessment for predicting outcomes after bioselection chemotherapy in larynx cancer: A secondary analysis of two prospective trials. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 30-36.	0.9	0